Aptevo Therapeutics Inc. (NASDAQ:APVO) Shares Shorted: Short Interest Up 59.0% in September

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the recipient of a significant growth in short interest in the month of September. As of September 15th, there was short interest totaling 187,942 shares, a growth of 59.0% from the August 31st total of 118,188 shares. Based on an average daily trading volume, of 336,643 shares, the short-interest ratio is currently 0.6 days. Approximately 10.4% of the shares of the company are sold short.

Aptevo Therapeutics Stock Performance

Shares of APVO traded down $0.04 during mid-day trading on Wednesday, reaching $1.82. 24,079 shares of the company’s stock traded hands, compared to its average volume of 106,352. The business’s 50-day moving average price is $2.80 and its 200-day moving average price is $4.02. The stock has a market capitalization of $3.29 million, a P/E ratio of -0.04 and a beta of 1.60. Aptevo Therapeutics has a 12 month low of $1.37 and a 12 month high of $35.64.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($5.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($6.02) by $0.71. Equities research analysts anticipate that Aptevo Therapeutics will post -17.04 EPS for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of Aptevo Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a report on Friday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Aptevo Therapeutics

Aptevo Therapeutics Inc (NASDAQ:APVO) is a biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to engage the immune system and direct it against specific disease-related cells or targets.

Aptevo’s pipeline is based primarily on its ADAPTIR and ADAPTIR-FLEX platform technologies, which support the development of engineered, multispecific antibodies. These programs have included investigational candidates such as APVO436, an immune-cell engager being studied in hematologic malignancies, and other compounds aimed at treating solid tumors and blood cancers.